Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.
Aim(s): Describe the incidence and prevalence, and characterize HCRU and treatment modalities in pts with adv WD NET of GI or lung origin in Southwest Finland.
Materials and methods: Retrospective data was collected from Auria Biobank (2004-2013). Electronic records were used to identify pts with WD GI or lung NET (grade 1 and 2; Ki-67 <20%). Data on HCRU, including hospital treatment periods, hospital days, outpatient visits, medical procedures, and laboratories were collected.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Lotte Gaasvik
To read results and conclusion, please login ...
Further abstracts you may be interested in